In particular, a bone marrow analysis is necessary to determine whether the CD34 expression identified in this study is an aberrant immunophenotype, precursor lymphoma, or acute lymphoblastic leukemia, and peripheral blood tests are insufficient. This evidence concerns the gene CD34 and lymphoma.